Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: A comprehensive review

Respiratory Research

Volumn 5, Issue , 2004, Pages

  Kankaanranta, Hannu ^a,b   Lahdensuo, Aarne ^b   Moilanen, Eeva ^a,b   Barnes, Peter J ^c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Asthma; Inhaled corticosteroids; Leukotriene antagonists; Long acting 2 agonists; Theophylline

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID DERIVATIVE; FLUNISOLIDE; FLUTICASONE PROPIONATE; FORMOTEROL; GLUCOCORTICOID; HYDROCORTISONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MOMETASONE FUROATE; MONTELUKAST; OSTEOCALCIN; PLACEBO; PRANLUKAST; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TRIAMCINOLONE ACETONIDE; ZAFIRLUKAST; ANTIASTHMATIC AGENT; CORTICOSTEROID;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BEHAVIOR DISORDER; BRONCHODILATING ACTIVITY; CANDIDIASIS; CATARACT; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DYSPHONIA; EXTRASYSTOLE; FORCED EXPIRATORY VOLUME; GLAUCOMA; GROWTH RETARDATION; HEART ATRIUM FIBRILLATION; HOARSENESS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; INFECTION RISK; INTRAOCULAR HYPERTENSION; LOW DRUG DOSE; LUNG BIOPSY; LUNG FUNCTION; LUNG LAVAGE; MEDLINE; META ANALYSIS; METERED DOSE INHALER; MUSCLE CRAMP; OSTEOPOROSIS; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PHARYNGITIS; PHARYNX DISEASE; POWDER INHALER; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SKIN BRUISING; SKIN DISEASE; SORE THROAT; SUPRAVENTRICULAR TACHYCARDIA; SUSTAINED DRUG RELEASE; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL; ADJUVANT CHEMOTHERAPY; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; ASTHMA; CHEMOTHERAPY, ADJUVANT; DRUG COMBINATIONS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 25444465385     PISSN: 1465993X     EISSN: None     Source Type: Journal    
DOI: 10.1186/1465-9921-5-17     Document Type: Review

References (121)

1. NHLBI. National Asthma Education and Prevention Program, Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. In NIH Publication No. 97-4051 Bethesda, MD: US Department of Health and Human Services; 1997.
2. NHLBI. Global Initiative for Asthma: Global strategy for astma management and prevention. NIH Publication No 02-3659 2002.
3. Barnes PJ, Pedersen S, Busse WW: Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998, 157:S1-S53.
4. Martin RJ, Szefler SJ, Chincilli VM, Kraft M, Dolovich M, Boushey HA, Cherniak RM, Craig TJ, Drazen JM, Fagan JK, Fahy JV, Fish JE, Ford JG, Israel E, Kunselman SJ, Lazarus SC, Lemanske RF Jr, Peters SP, Sorkness CA: Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002, 165:1377-1383.
5. The British Thoracic Society: The British guidelines on asthma management 1995 review and position statement. Thorax 1997,[52(Suppl 1):S1-S20.
6. NHLBI. Global Initiative for Asthma: Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. NIH publication no. 95-3659 1995.
7. Lipworth BJ, Jackson CM: Second-line controller therapy for persistent asthma uncontrolled on inhaled corticosteroids. The step 3 dilemma. Drugs 2002, 62:2315-2332.
8. Masoli M, Holt S, Beasley R: What to do at step 3 asthma guidelines - increase the dose of inhaled corticosteroids or add a long-acting β-agonist drug. J Allergy Clin Immunol 2003, 112:10-11.
9. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R: Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001, 323:253-256.
10. Adams N, Bestall J, Jones P: Inhaled beclomethasone at different doses for long-term asthma (Cochrane Review). In In: The Cochrane Library Issue 3 Oxford:Update Software; 2001.
11. Adams N, Bestall J, Jones PW: Inhaled fluticasone propionate for chronic asthma (Cochrane Review). In In: The Cochrane Library Issue 3 Oxford:Update Software; 2001.
12. Adams N, Bestall J, Jones P: Inhaled budesonide at different doses for chronic asthma (Cochrane Review). In In: The Cochrane Library Issue 1 Oxford:Update Software; 2002.
13. Shrewsbury S, Pyke S, Britton M: Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000, 320:1368-1373.
14. Bousquet J, Ben-Joseph R, Messonnier M, Alemao E, Gould AL: A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther 2002, 24:1-20.
15. Heyneman CA, Crafts R, Holland J, Arnold AD: Fluticasone versus salmeterol/low-dose fluticasone for long-term asthma control. Ann Pharmacother 2002, 36:1944-1949.
16. Powell H, Gibson PG: Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Austral 2003, 178:223-225.
17. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary. Controlled Clin Trials 1996, 17:1-12.
18. Busse WW, Brazinsky S, Jacobson K, Stricker W, Schmitt K, Vanden Burgt J, Donnell D, Hannon S, Colice GL: Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999, 104:1215-1222.
19. Miyamoto T, Takahashi T, Nakajima S, Makino S, Yamakido M, Mano K, Nakashima M, Tollemar U, Selroos O: A double-blind, placebocontrolled dose-response study with budesonide Turbuhaler in Japanese asthma patients. Japanese Pulmicort Turbuhaler study group. Respirology 2000, 5:247-256.
20. Dahl R, Lundback B, Malo JL, Mazza JA, Nieminen MM, Saarelainen P, Barnacle H: A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group. Chest 1993, 104:1352-1358.
21. Chervinsky P, van As A, Bronsky EA, Dockhorn R, Noonan M, LaForce C, Pleskow W: Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 1994, 94:676-683.
22. Pearlman DS, Noonan MJ, Tashkin DP, Goldstein MF, Hamedani AG, Kellerman DJ, Schaberg A: Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Ann Allergy Asthma Immunol 1997, 78:356-362.
23. Sheffer AL, LaForce C, Chervinsky P, Pearlman D, Schaberg A, the fluticasone propionate asthma study group: Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. J Fam Pract 1996, 42:369-375.
24. Wasserman SI, Gross GN, Schoenwetter WF, Munk ZM, Kral KM, Kellerman DJ: A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. J Asthma 1996, 33:265-274.
25. Wolfe JD, Selner JC, Mendelson LM, Hampel F, Schaberg A: Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study. Clin Ther 1996, 18:635-646.
26. Nathan RA, Li JT, Finn A, Jones R, Payne JE, Wolford JP, Harding SM: A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest 2000, 118:296-302.
27. Bernstein DI, Berkowitz RB, Chervinsky P, Dvorin DJ, Finn AF, Gross GN, Karetzky M, Kemp JP, LaForce C, Lumry W, Mendelson LM, Nelson H, Pearlman D, Rachelefsky G, Ratner P, Repsher L, Segal AT, Selner JC, Settipane GA, Wanderer A, Cuss FM, Nolop KB, Harrison JE: Dose-ranging study of a new steroid for asthma: mometasone furoate dry powder inhaler. Respir Med 1999, 93:603-612.
28. Bousquet J, D'Urzo AD, Hedlin G, Barraza CH, Boulet LP, Suarez-Chacon R, Harnest U, Lundback B, Martinez Morales G, Nieminen MM, Nolop KB, Visser S, Lutsky BN: Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler. Eur Respir J 2000, 16:808-816.
29. O'Connor B, Bonnaud G, Haahtela T, Luna JM, Querfurt H, Wegener T, Lutsky BN: Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol 2001, 86:397-404.
30. Welch MJ, Levy S, Smith JA, Feiss G, Farrar JR: Dose-ranging study of the clinical efficacy of twice-daily triamcinolone acetonide inhalation aerosol in moderately severe asthma. Chest 1997, 112:597-606.
31. Welch M, Bernstein D, Gross G, Kane RE, Banerji D: A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Azmacort HFA Study Group. Chest 1999, 116:1304-1312.
32. Adams N, Bestall JM, Jones PW: Inhaled fluticasone at different doses for chronic asthma (Cochrane Review). In In The Cochrane Library Issue 1 Oxford:Update Software; 2003.
33. Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, Townley RG: Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998, 101:457-463.
34. Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL: What are minimal important changes for asthma measures in a clinical trial? Eur Respir J 1999, 14:23-27.
35. Crim C, Pierre LN, Daley-Yates PT: A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 2001, 23:1339-1354.
36. Chervinsky P, Nelson HS, Bernstein DI, Berkowitz RA, Siegel SC: Comparison of mometasone furoate administered by metered dose inhaler with beclomethasone dipropionate. Int J Clin Pract 2002, 56:419-425.
37. Jacobson K, Chervinsky P, Noonan M, Kane RE, Banerji D, Uryniak T: Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group. Ann Allergy Asthma Immunol 1999, 83:327-333.
38. Wilson AM, Lipworth BJ: Dose-response evaluation of the therapeutic index for inhaled budesonide in patients with mild-to-moderate asthma. Am J Med 2000, 108:269-275.
39. Nielsen LP, Dahl R: Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function. Am J Respir Crit Care Med 2000, 162:2053-2057.
40. Swystun VA, Bhagat R, Kalra S, Jennings B, Cockcroft DW: Comparison of 3 different doses of budesonide and placebo on the early asthmatic response to inhaled allergen. J Allergy Clin Immunol 1998, 102:363-367.
41. Toogood JH, White FA, Baskerville JC, Fraher LJ, Jennings B: Comparison of the antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler. J Allergy Clin Immunol 1997, 99:186-193.
42. Jatakanon A, Kharitonov S, Lim S, Barnes PJ: Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax 1999, 54:108-114.
43. Taylor DA, Jensen MW, Kanabar V, Engelstatter R, Steinijans VW, Barnes PJ, O'Connor BJ: A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5′-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999, 160:237-243.
44. Silkoff PE, McClean P, Spino M, Erlich L, Slutsky AS, Zamel N: Dose-response relationship and reproducibility of the fall in exhaled nitric oxide after inhaled beclomethasone dipropionate therapy in asthma patients. Chest 2001, 119:1322-1328.
45. Jones SL, Herbison P, Cowan JO, Flannery EM, Hancox RJ, McLachlan CR, Taylor DR: Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship. Eur Respir J 2002, 20:601-608.
46. Inman MD, Watson RM, Rerecich T, Gauvreau GM, Lutsky BN, Stryszak P, O'Byrne PM: Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med 2001, 164:569-574.
47. Lipworth BJ: Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med 1999, 159:941-955.
48. Harrison LI, Colice GL, Donnell D, Soria I, Dockhorn R: Adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate: a 14-day dose-response study. J Pharm Pharmacol 1999, 51:263-269
49. McCubbin MM, Milavetz G, Grandgeorge S, Weinberger M, Ahrens R, Sargent C, Vaughan LM: A bioassay for topical and systemic effect of three inhaled corticosteroids. Clin Pharmacol Ther 1995, 57:455-460.
50. Wilson AM, Brewster HJ, Lipworth BJ: Dose-response comparison of systemic bioactivity with inhaled budesonide and triamcinolone acetonide in asthmatic adults. J Allergy Clin Immunol 1998, 102:751-756.
51. Wilson AM, McFarlane LC, Lipworth BJ: Dose-response effect for adrenal suppression with repeated twice daily inhaled fluticasone propionate and triamcinolone acetonide in adult asthmatics. Am J Respir Crit Care Med 1997, 156:1274-1277.
52. Clark DJ, Grove A, Cargill RI, Lipworth BJ: Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996, 51:262-266.
53. Clark DJ, Lipworth BJ: Evaluation of corticotropin releasing factor stimulation and basal markers of hypothalamic-pituitaryadrenal axis suppression in asthmatic patients. Chest 1997, 112:1248-1252.
54. Wilson AM, Lipworth BJ: Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. Br J Clin Pharmacol 1999, 48:579-585.
55. Wilson AM, Sims EJ, Lipworth BJ: Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment. Clin Endocrinol (Oxf) 1999, 50:329-335.
56. Altman LC, Findlay SR, Lopez M, Lukacsko P, Morris RJ, Pinnas JL, Ratner PH, Szefler SJ, Welch MJ: Adrenal function in adult asthmatics during long-term daily treatment with 800, 1,200, and 1,600 micrograms triamcinolone acetonide. Multicenter study. Chest 1992, 101:1250-1256.
57. Grahnen A, Eckernäs S-Å, Brundin RM, Ling-Andersson A: An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol 1994, 38:521-525.
58. Donnelly R, Williams KM, Baker AB, Badcock C-A, Day RO, Seale JP: Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study. Am J Respir Crit Care Med 1997, 156:1746-1751.
59. Derom E, Van Schoor J, Verhaeghe W, Vincken W, Pauwels R: Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma. Am J Respir Crit Care Med 1999, 160:157-161.
60. Brutsche MH, Brutsche IC, Munawar M, Langley SJ, Masterson CM, Daley-Yates PT, Brown R, Custovic A, Woodcock A: Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000, 356:556-561.
61. Harrison TW, Wisniewski A, Honour J, Tattersfield AE: Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 2001, 56:186-191.
62. Jarvis B, Faulds D: Inhaled fluticasone propionate. A review of its therapeutic efficacy at dosages <500 μg/d in adults and adolescents with mild to moderate asthma. Drugs 1999, 57:769-803.
63. Barnes PJ: Effect of β-agonists on inflammatory cells. J Allergy Clin Immunol 1999, 104:S10-S17.
64. 2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997, 155:704-710.
65. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999, 274:1005-1010.
66. 2-agonists and corticosteroids. Eur Respir J 2002, 19:182-191.
67. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A: Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997, 337:1405-1411.
68. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A: Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomized trial. Am J Respir Crit Care Med 2001, 164:1392-1397.
69. Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B, Thomson NC: Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003, 123:1480-1487.
70. Greening AP, Ind PW, Northfield M, Shaw G: Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994, 344:219-224.
71. Woolcock A, Lundback B, Ringdal N, Jacques LA: Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996, 153:1481-1488.
72. Baraniuk J, Murray JJ, Nathan RA, Berger WE, Johnson M, Edwards LD, Srebro S, Rickard KA: Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. Chest 1999, 116:625-632.
73. Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K: The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol 1999, 82:383-389.
74. Kelsen SG, Church NL, Gillman SA, Lanier BQ, Emmett AH, Rickard KA, Anderson WH: Salmeterol added to inhaled corticosteroid therapy is superior to doubling the dose of inhaled corticosteroids: a randomized clinical trial. J Asthma 1999, 36:703-715.
75. Murray JJ, Church NL, Anderson WH, Bernstein DI, Wenzel SE, Emmett A, Rickard KA: Concurrent use of salmeterol with inhaled corticosteroids is more effective than inhaled corticosteroid dose increases. Allergy Asthma Proc 1999, 20:173-180.
76. van Noord JA, Schreurs AJ, Mol SJ, Mulder PG: Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999, 54:207-212.
77. Vermetten FA, Boermans AJ, Luiten WD, Mulder PG, Vermue NA: Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids. J Asthma 1999, 36:97-106.
78. Ind PW, Dal Negro R, Colman NC, Fletcher CP, Browning D, James MH: Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 2003, 97:555-562.
79. Juniper EF, Svensson K, O'Byrne PM, Barnes PJ, Bauer CA, Lofdahl CG, Postma DS, Pauwels RA, Tattersfield AE, Ullman A: Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J 1999, 14:1038-1043.
80. Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, Zhang J: Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 1997, 10:646-651.
81. Bouros D, Bachlitzanakis N, Kottakis J, Pfister P, Polychronopoulos V, Papadakis E, Constantopoulos S, Froudarakis M, Sichletidis L, Siafakas N: Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur Respir J 1999, 14:627-632.
82. Kankaanranta H, Lindsay MA, Giembycz MA, Zhang X, Moilanen E, Barnes PJ: Delayed eosinophil apoptosis in asthma. J Allergy Clin Immunol 2000, 106:77-83.
83. Nielson CP, Hadjokas NE: Beta-adrenoceptor agonists block corticosteroid inhibition in eosinophils. Am J Respir Crit Care Med 1998, 157:184-191.
84. Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM: A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med 2000, 161:996-1001.
85. 2-agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med 1999, 160:1493-1499.
86. Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH: Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994, 150:1006-1011.
87. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR: Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998, 158:924-930.
88. 2-agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med 2001, 164:117-121.
89. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, Lofdahl CG, Pauwels RA, Ullman A: Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999, 160:594-599.
90. Matz J, Emmett A, Rickard K, Kalberg C: Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 2001, 107:783-789.
91. Dworski R, FitzGerald GA, Oates JA, Sheller JR: Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994, 149:953-959.
92. 4 excretion. Am Rev Respir Dis 1993, 147:1472-1476.
93. Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, Konstantopoulos S, Rojas R, van Noord JA, Pons M, Gilles L, Leff JA, for the clinical outcomes with montelukast as a partner agent to corticosteroid therapy (COMPACT) international study group: Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003, 58:211-216.
94. Vaquerizo MJ, Casan P, Castillo, Perpina M, Sanchis, Sobradillo V, Valencia A, Verea H, Viejo JL, Villasante C, Gonzalez-Esteban J, Picado C: Effect of added montelukast to inhaled budesonide on control of mild to moderate asthma. Thorax 2003, 58:204-211.
95. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, Zhang J, Reiss TF: Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 1999, 160:1862-1868.
96. Robinson DS, Campbell D, Barnes PJ: Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001, 357:2007-2011.
97. Currie GP, Lee DKC, Haggart K, Bates CE, Lipworth BJ: Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 2002, 167:1232-1238.
98. O'Sullivan S, Akveld M, Burke CM, Poulter LW: Effect of addition of montelukast to inhaled fluticasone propionate on airway inflammation. Am J Respir Crit Care Med 2003, 167:745-750.
99. Leigh R, Vethannayagam D, Yoshida M, Watson RM, Rerecich T, Inman MD, O'Byrne PM: Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med 2002, 166:1212-1217.
100. Virchow JC, Prasse A, Naya I, Summerton L, Harris A, the Zafirlukast Study Group: Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 2000, 162:578-585.
101. Ducharme FM: Anti-leukotriene as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ 2002, 324:1545-1551.
102. Ducharme F, Hicks G, Kakuma R: Addition of anti-leukotriene agents to inhaled corticosteroids for chronic asthma (Cochrane Review). In In: The Cochrane Library Issue 1 Oxford:Update Software; 2003.
103. Weinberger M, Hendeles L: Theophylline in asthma. N Engl J Med 1996, 334:1380-1388.
104. Rivington RN, Boulet LP, Cote J, Kreisman H, Small DI, Alexander M, Day A, Harsanyi Z, Darke AC: Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on high-dose inhaled steroids. Am J Respir Crit Care Med 1995, 151:325-332.
105. Youngchaiyud P, Permpikul C, Suthamsmai T, Wong E: A double-blind comparison of inhaled budesonide, long-acting theophylline, and their combination in treatment of nocturnal asthma. Allergy 1995, 50:28-33.
106. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ: A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 1997, 337:1412-1418.
107. Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N, Steffen H, Leichtl S, Rathgeb F, Keller A, Steinijans VW: Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 1997, 10:2754-2760.
108. Lim S, Jatakanon A, Gordon D, Macdonald C, Chung KF, Barnes PJ: Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax 2000, 55:837-841.
109. Nelson HS, Busse WW, Kerwin E, Church N, Emmett A, Rickard K, Knobil K: Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000, 106:1088-1095.
110. Ringdal N, Eliraz A, Pruzinec P, Weber H-H, Mulder PGH, Akveld M, Bateman ED: The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 2003, 97:234-241.
111. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening AP, Haahtela T, Holgate ST, Picado C, Menten J, Balachandra Dass S, Leff JA, Polos PG: Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double-blind, randomised, comparative trial. BMJ 2003, 327:891.
112. Fish JE, Israel E, Murray JJ, Emmett A, Boone R, Yancey SW, Rickard KA: Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001, 120:423-430.
113. Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ: Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 2001, 119:1021-1026.
114. Nelson HS, Nathan RA, Kalberg C, Yancey SW, Rickard KA: Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. MedGenMed 2001, 3:3.
115. Busse W, Nelson H, Wolfe J, Kalberg C, Yancey SW, Rickard KA: Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J Allergy Clin Immunol 1999, 103:1075-1080.
116. Yardakul AS, Calisir HC, Tunctan B, Ögretensoy M: Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma. Respir Med 2002, 96:322-329.
117. Dompeling E, van Grunsven PM, van Schayck CP, Folgering H, Molema J, van Weel C: Treatment with inhaled steroids in asthma and chronic bronchitis: long-term compliance and inhaler technique. Fam Pract 1992, 9:161-166.
118. Bosley CM, Parry DT, Cochrane GM: Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance? Eur Respir J 1994, 7:504-509.
119. Kelloway JS, Wyatt RA, Adlis SA: Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994, 154:1349-1352.
120. Simon RA: Update on inhaled corticosteroids: safety, compliance, and new delivery systems. Allergy Asthma Proc 1999, 20:161-165.
121. Gibson PG, Coughlan J, Wilson AJ, Abramson M, Bauman A, Hensley MJ, Walters EH: Self-management education and regular practitioner review for adults with asthma (Cochrane Review). In In: The Cochrane Library Issue 1 Oxford:Update Software; 2002.